The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Honoraria - Bristol-Myers Squibb; MSD; Roche/Genentech
Michele Maio
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Micaela Hernberg
Consultant or Advisory Role - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Henrik Schmidt
Consultant or Advisory Role - Bristol-Myers Squibb; Roche
Honoraria - Bristol-Myers Squibb; Roche
Ian Waxman
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Claus Garbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche; SOBI
Céleste Lebbé
Consultant or Advisory Role - Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Expert Testimony - Roche (U)
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche